Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

TDOC investors were burned when the company reported $6.67B of net losses for FQ1'22. It is evident that TDOC finally admitted to their Livongo folly, though it is the investors who are feeling the pain.

Teladoc: Let's Apply Aloe Vera On The Burns

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, announces that it is investigating Teladoc Health Inc. ("Teladoc" or the "Company") (NYSE: TDOC) for potential violations of the federal securities laws. Shares of Teladoc Health Inc. were plummeted as much as 48% after the telemedicine company reported full-year revenue and profit guidance that fell short of analyst expectations on Wednesday, April 27, 2022. Teladoc extends a slump t

SHAREHOLDER ALERT - Labaton Sucharow Investigating Teladoc Health Inc. – TDOC

TDOC stock is down over 40% after reporting a $6.6 billion goodwill impairment charge. This is bad news for Ark Invest and Cathie Wood.

Cathie Wood Keeps Buying Teladoc (TDOC) Stock. Here's Why.

Could this quarter be a thesis breaker for shareholders?

Why Teladoc (TDOC) Stock Crashed Today

The digital healthcare pioneer delivered abysmal financial results.

Why Teladoc Health Stock Cratered on Thursday

Teladoc is held widely across ARK Invest's funds.

Cathie Wood's ARK Bet Big on Tumbling Teladoc. These Funds Did Too.

While a number of names on Wall Street have provided traders with upbeat quarterly results this morning, Teladoc Health Inc (NYSE:TDOC) is not one of them.

Teladoc Stock Plummets to 4-Year Low After Dismal Full-Year Forecast

An enormous write-down on its chronic-care business is just part of the problem.

Why Teladoc Health's Latest Earnings Call Was So Disappointing

Ark Invest bought about 100,000 shares of Teladoc across its various ETFs as recently as Tuesday, and more than 40,000 shares on Monday.

Teladoc implodes 44% after massive first-quarter loss, costing Cathie Wood's ARK more than $400 million

Teladoc Health Inc (NYSE: TDOC) shares are trading significantly lower Thursday after the company reported weak financial results. Teladoc said first-quarter revenue increased 25% year-over-year to $565.4 million, which came in below the $568.8 million estimate.

Why Teladoc Stock Is Diving Today

Shares of Teladoc Health Inc. were plunging 40% in premarket trading Thursday after the telemedicine company cut its full-year outlook, prompting a handful of analysts who once recommended the stock to jump ship.

Teladoc's ‘quarter for the bears' sparks an exodus of bulls

The price of Teladoc stock has been in the red for the better of April and despite closing the market at a drop of 3.08%, it has gone ahead to register a 43% drop over in the premarket. To help stock traders who want to take advantage of the Teladoc stock dip, Invezz has created […] The post Buying the dip: Teladoc stock is down by 43% in premarket after a $6.67B in Q1 appeared first on Invezz.

Buying the dip: Teladoc stock is down by 43% in premarket after a $6.67B in Q1

Teladoc Health Inc (NYSE: TDOC) posted a Q1 EPS loss of $(41.58) compared to $(1.31) a year ago. Q1 EPS loss included a non-cash goodwill impairment charge of $(41.11), stock-based compensation expense of $(0.38), and amortization of acquired intangibles of $(0.31) per share.

Teladoc Health Posts Deeper Loss On Goodwill Impairment Charge Of $6.6B, Cuts FY22 Guidance

Teladoc (TDOC) delivered earnings and revenue surprises of 14.55% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Reports Q1 Loss, Lags Revenue Estimates

Teladoc Health Inc. (NYSE:TDOC ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Patrick Feeley - Head of IR Jason Gorevic - CEO Mala Murthy - CFO Conference Call Participants Lisa Gill - JPMorgan Ryan Daniels - William Blair Sandy Draper - Guggenheim Securities Sean Dodge - RBC Capital Markets Richard Close - Canaccord Genuity Stephanie Davis - SVB Leerink Daniel Grosslight - Citigroup Charles Rhyee - Cowen Jessica Tassan - Piper Sandler Allen Lutz - Bank of America George Hill - Deutsche Bank Stan Berenshteyn - Wells Fargo Cindy Motz - Goldman Sachs Operator Good afternoon. Thank you for attending today's Teladoc 2022 First Quarter Earnings Conference Call.

Teladoc Health Inc. (TDOC) CEO Jason Gorevic on Q1 2022 Results - Earnings Call Transcript

Teladoc Health Inc shares (NYSE: TDOC) tanked 40% in extended trading on Wednesday after the virtual healthcare company said it took an impairment charge worth $6.60 billion in Q1 and lowered its guidance for the full year. Teladoc Q1 earnings snapshot Lost $6.67 billion in fiscal Q1 versus the year-ago figure of $200 million.

What made Teladoc shares tank 40% in extended trading?

The telemedicine company took a noncash goodwill impairment charge of $6.6 billion in the first quarter, dragging down its results.

Teladoc Tumbled 38% After Big First-Quarter Loss. Is It Just a Pandemic Play?

Meta's Way Up After Hours, but This High-Growth Stock Wasn't as Fortunate

Teladoc Health Inc (NYSE: TDOC) shares are trading significantly lower in Wednesday's after-hours session after the company reported financial results. Teladoc said first-quarter revenue increased 25% year-over-year to $565.4 million, which came in below the $568.8 million estimate.

Why Teladoc Shares Are Plunging After Hours

Shares of Teladoc Health Inc. were slammed in after-hours trading Wednesday, after the telemedicine company took an impairment charge of more than $6.5 billion and slashed its full-year outlook.

Teladoc stock plunges more than 30% after earnings outlook slashed, massive impairment charge

PURCHASE, NY, April 27, 2022 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the first quarter ended March 31, 2022.

Teladoc Health Reports First Quarter 2022 Results

Arthur J. Gallagher & Co.

Antero Resources

W. P. Carey

Weyerhaeuser

Five companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: WPC, WY, TDOC, AR and AJG.

5 Stocks to Buy Ahead of Q1 Earnings Results This Week

CRISPR Therapeutics

Block

These Cathie Wood Stocks have their risks but offer a massive upside potential ahead The post 3 Cathie Wood Stocks to Count on in Q2 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

3 Cathie Wood Stocks to Count on in Q2

The company taps an executive with diverse experience to be its new chief medical officer.

Why Teladoc Health Stock Crushed the Market Today

Despite its recent struggles in the stock market, there are still reasons to be optimistic about this company.

News for Teladoc Stock (TDOC)